HALO vs. RPRX: Halozyme Therapeutics vs. Royalty Pharma Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while RPRX is classified in Pharmaceuticals.

Halozyme Therapeutics (HALO) has more than two decades of public-market history since March 16, 2004, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Royalty Pharma (RPRX) at 12.09% also sits in the top quartile.

Both Halozyme Therapeutics (HALO) at 26.93% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Halozyme Therapeutics (HALO) at 59.84% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Halozyme Therapeutics (HALO) at -25.36% and Royalty Pharma (RPRX) at 23.09% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

Only one side’s leverage can be read here: Royalty Pharma (RPRX) carries debt-to-equity ratio of 0.88 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Halozyme Therapeutics (HALO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

Halozyme Therapeutics (HALO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Royalty Pharma (RPRX) reports 4.39, ranking against industry peers normally.

Valuation Metrics